July 23, 2018 10:10 AM EDT

Pfizer/Merck KGaA launch solid tumor combo study with Leap; AstraZeneca and Immunomedics to test ADC cancer combo

Brittany Meiling

→ Pfizer and Merck KGaA are teaming up with Leap Therapeutics $LPTX to evaluate the small Cambridge, MA-based company’s drug in a combo with …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Pfizer/Merck KGaA launch solid tumor combo study with Leap; AstraZeneca and Immunomedics to test ADC cancer combo

Brittany Meiling

Sign up to read this article for free.

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

CBER's deputy director departs as staff shakeup continues

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

FDA approves first drug to treat ultra-rare lipid storage disease

Will CRISPR matter?

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Pfiz­er/Mer­ck KGaA launch sol­id tu­mor com­bo study with Leap; As­traZeneca and Im­munomedics to test ADC can­cer com­bo

Brittany Meiling

Sign up to read this article for free.

Blue­bird bio to sell to in­vest­ment funds af­ter strug­gling to make mon­ey from gene ther­a­pies

CBER's deputy di­rec­tor de­parts as staff shake­up con­tin­ues

Eli Lil­ly stock­piles $548M of oral weight loss drug ahead of launch

FDA ap­proves first drug to treat ul­tra-rare lipid stor­age dis­ease

Will CRISPR mat­ter?

Trust­ed pro­tec­tion: Why the cur­rent meningo­coc­cal vac­ci­na­tion sched­ule shouldn’t change with­out strong ev­i­dence

Pfizer/Merck KGaA launch solid tumor combo study with Leap; AstraZeneca and Immunomedics to test ADC cancer combo

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

CBER's deputy director departs as staff shakeup continues

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

FDA approves first drug to treat ultra-rare lipid storage disease

Will CRISPR matter?

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence